Suchergebnisse - "Myeloma"

PubPharm (39.809)

21

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Stock, S. | Fertig, L. | Gottschlich, A. | +12

22

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

enthalten in: Cancer | 2024

von Suvannasankha, A. | Bahlis, N. | Trudel, S. | +17

23

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma

enthalten in: Cancer immunology immunotherapy | 2024

von Stock, S. | Fertig, L. | Gottschlich, A. | +12

24

Comparison of trace elements in peripheral blood and bone marrow of newly diagnosed multiple myeloma patients

enthalten in: Clinical and experimental medicine | 2024

von Kul, A. | Ozturk Kurt, B.

25

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies : A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation

enthalten in: ClinicalTrials.gov | 2024

26

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions : A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives

enthalten in: ClinicalTrials.gov | 2024

27

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma : A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

28

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab : Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab

enthalten in: ClinicalTrials.gov | 2024

29

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM : A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

30

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) : A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024